ARGX Stock — argenx SE

argenx SE (ARGX)

Updated October 16, 2026.

ARGX is a Stock. Total return is 3461.5% over the past 9.4 years, 3187.9 points ahead of SPY at 273.6%.

argenx SE is a commercial-stage biopharmaceutical company that develops therapies for autoimmune diseases, with approved products including VYVGART for generalized myasthenia gravis and immune thrombocytopenia, and a pipeline of candidates targeting conditions such as chronic inflammatory demyelinating polyneuropathy, Sjögren's disease, and systemic sclerosis. The company does not currently distribute dividends. argenx appeals to growth-oriented investors seeking exposure to biopharmaceutical development and commercialization rather than current income.

ARGX performance versus SPY

Price and return data through 2026-10-16.

Total return is 3461.5% over the past 9.4 years, 3187.9 points ahead of SPY at 273.6%. Over the past year its total return — price change plus distributions reinvested — is -2.2%. Its deepest 1-year drawdown was 28.6%.

ARGX key facts

Asset type

Stock

Asset class

Equity

Inception date

05/18/2017

Distribution frequency

None

Last close

$819.14 (as of 2026-10-16)

Market cap

$51,512,498,656

Average volume

388982.0

Beta

-0.043

Payout ratio

0.0%

P/E ratio

31.22

Forward P/E

25.9067

EPS

$26.24

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ARGX risks and drawbacks

The deepest 1-year drawdown on record here is 28.6%.

Who may consider ARGX — and who may not

It is a weaker fit for investors who need monthly cash flow (ARGX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ARGX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions